Clinical Trials
6 trialsNCT00720785 2026-05-07
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02333604 2026-04-23
CER
Cancer Support Community, Research and Training Institute, Philadelphia
Recruiting
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT04090619 2026-02-13
Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers
M.D. Anderson Cancer Center
Active not recruiting
NCT04094610 2025-11-19
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05400122 2025-11-12
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Phase 1 Suspended